Phase II Study of Bevacizumab, Temozolomide and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma

PURPOSE: Bevacizumab is associated with decreased vascular permeability that allows for more aggressive radiotherapy schedules. We conducted a phase II trial in newly-diagnosed glioblastoma utilizing a novel hypofractionated stereotactic radiotherapy (HFSRT) schedule combined with temozolomide and b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Cancer Res
Hauptverfasser: Omuro, Antonio, Beal, Kathryn, Gutin, Philip, Karimi, Sasan, Correa, Denise D., Kaley, Thomas J., DeAngelis, Lisa M., Chan, Timothy A., Gavrilovic, Igor T., Nolan, Craig, Hormigo, Adilia, Lassman, Andrew B., Mellinghoff, Ingo, Grommes, Christian, Reiner, Anne S., Panageas, Katherine S., Baser, Raymond E., Tabar, Viviane, Pentsova, Elena, Sanchez, Juan, Barradas-Panchal, Renata, Zhang, Jianan, Faivre, Geraldine, Brennan, Cameron W., Abrey, Lauren E., Huse, Jason T.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2014
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4523080/
https://ncbi.nlm.nih.gov/pubmed/25107913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0822
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge